



# Seabreeze

## STAT ASTHMA

### eCRF Completion Guidelines

---

Client: Connect Biopharma

Protocol: CBP-201-206

Clinical Data Management System (CDMS):  
Medrio

Prepared by:

Lindsey Falor  
Principal Clinical Data Manager  
Precision for Medicine (Precision)  
Email: [Lindsey.Falor@precisionformedicine.com](mailto:Lindsey.Falor@precisionformedicine.com)

Version: 3.0\_06MAR2026

CCG APPROVAL

The signatures below indicate approval of the CCG file titled: Connect Biopharma eCRF Completion Guidelines\_V3.0\_06MAR2026.pdf

Signed by:  
*Lindsey Falor*  
Signer Name: Lindsey Falor  
Signing Reason: I approve this document  
Signing Time: 06-Mar-2026 | 1:43:30 PM CST  
612C8FFAA3774D91BAD87F9AC61126B1

\_\_\_\_\_  
Signature

Lindsey Falor

\_\_\_\_\_  
Lindsey Falor

**Precision for Medicine**

06-Mar-2026

\_\_\_\_\_  
Date

Principal Clinical Data Manager

\_\_\_\_\_  
Principal Clinical Data Manager

Signed by:  
*Marisa Jones*  
Signer Name: Marisa Jones  
Signing Reason: I approve this document  
Signing Time: 06-Mar-2026 | 11:27:17 AM PST  
DA7DCEFC9A1D4049B0A84A836FEDFF75

\_\_\_\_\_  
Signature

Marisa Jones

\_\_\_\_\_  
Marisa Jones

**Connect Biopharma**

06-Mar-2026

\_\_\_\_\_  
Date

Clinical Trials Manager

\_\_\_\_\_  
Clinical Trials Manager

**REVISION HISTORY**

Version	Summary/Reason for changes	Revision Date
V1.0	Initial Approval	NA
V1.1	<p>Eligibility CRF – Text added to clarify CRFs which will not appear in EDC if protocol version 2.0 or 3.0 was selected.</p> <p>12-Lead ECG – Text added for RR interval to accept 4 digits values Smoking History CRF – IRT integration removed from Smoking History status question</p> <p>Subsequent Asthma Exacerbation Episode and Index Asthma Exacerbation Follow-Up – instructional text added for site to enter Urgent Care and Emergency Room details in the CRF</p> <p>Spirometry/FeNO – Text added to clarify row completion</p> <p>Concomitant medications – Reminder added to separate steroid courses Accessing Your Project – Medrio e-Learning module (41.6) specified for site staff</p> <p>General eCRF Entry Guidelines – Specified that data entry is expected within 5 business days</p> <p>Informed Consent – version number changed to version date</p>	12Dec2025
V2.0	Final version	18DEC2025
V2.1	<p>Updated to reflect Lead Data Manager transition from Munim Saeed to Lindsey Falor (Updated references of Munim to Lindsey)</p> <p>Removed Zachary Kaminski phone number within “DM Team Personnel” section, as phone number is no longer valid.</p> <p>Updated the “CRF Book / Visit Map” section to reflect that V2 (Visit 2) is automatically active at participant creation.</p> <p>Added “Treatment Failure” EDC form</p>	03MAR2026

<p>V2.2</p>	<p>Updated Hematology (Local Lab) section with further guidance on the [If abnormal, clinically significant?] data point.</p> <p>Updated Chemistry (Local Lab) section with further guidance on the [If abnormal, clinically significant?] data point.</p> <p>Removed reference to clinically significant data point for Urinalysis (Local Lab).</p> <p>Updated the [Indication] guidance for the Concomitant Medications section, pertaining to historical asthma exacerbations.</p> <p>Revised the CRF Book / Visit Map section, also including “Table 4: Specific Visit Activation Criteria”. Changed Data Manager contact information.</p> <p>Added a table header/title to all tables within the document, including “Table 5: Treatment Failure Follow-up Date Entry Guidance” at Treatment Failure form section.</p> <p>Revised Index Asthma Exacerbations Follow-Up form to more accurately indicate when hospitalizations, urgent care, and ER visits should be entered.</p> <p>Revised Subsequent Asthma Exacerbation Episode form to more accurately indicate when hospitalizations, urgent care, and ER visits should be entered.</p> <p>Updated Eligibility form to remove reference of V2 activation, as V2 is now active at subject creation.</p> <p>Revised the “Resolving Queries” section to remove reference to screenshots.</p>	<p>05MAR2026</p>
<p>V3.0</p>	<p>Final version</p>	<p>06MAR2026</p>

**REVISION HISTORY ..... 3**

**OVERVIEW .....8**

    DM TEAM PERSONNEL.....8

    MEDRIO.....8

**GETTING STARTED .....8**

    SUPPORTED BROWSERS .....8

**ACCESSING YOUR PROJECT.....9**

    FIRST TIME LOGIN .....10

    SUBSEQUENT LOGINS.....12

    CHANGING YOUR PASSWORD.....12

    PASSWORD RESET.....13

    EDC SUPPORT / HELP .....13

    SITE-LEVEL ACCESS .....13

    GETTING MORE HELP .....13

    HOME PAGE .....14

    CREATING A NEW PARTICIPANT .....15

    ACCESSING PARTICIPANTS .....15

    ENTER DATA TAB .....15

    MANAGE TAB .....18

**GENERAL ECRF ENTRY GUIDELINES .....18**

    SOURCE DOCUMENTATION .....19

    LEADING ZEROES.....19

    RADIO BUTTONS.....19

    KEYBOARD SHORTCUTS .....19

    DATES .....19

    TIME FORMAT.....20

    LOG AND REPEAT ECRFS .....21

    UNSCHEDULED ECRFS.....23

    OTHER, SPECIFY FIELDS / YES/NO QUESTIONS.....23

**CRF BOOK / VISIT MAP.....24**

**QUERIES.....29**

    RESOLVING QUERIES .....30

**ACCESSING CCGS .....30**

**PROJECT SPECIFIC INFORMATION .....31**

**GUIDELINES -PER PROJECT SPECIFIC ECRFS .....32**

VISIT DATE.....32

INFORMED CONSENT .....32

ELIGIBILITY .....33

RANDOMIZATION .....34

DEMOGRAPHICS.....34

MEDICAL AND SURGICAL HISTORY.....34

ASTHMA HISTORY AND EXACERBATION HISTORY.....36

V1A FOLLOW-UP PHONE LOG .....37

VITAL SIGNS.....37

HEIGHT/WEIGHT.....38

PHYSICAL EXAM.....38

PREGNANCY TEST .....39

LABORATORY TEST.....39

CONCOMITANT MEDICATIONS .....40

CONCOMITANT PROCEDURES .....41

ANY ADVERSE EVENTS? .....42

ADVERSE EVENTS.....43

SERIOUS ADVERSE EVENTS .....46

TREATMENT FAILURE .....47

12-LEAD ECG (LOCAL LAB).....51

PK SAMPLE .....51

BIOMARKER SAMPLE .....51

IMMUNOGENICITY SAMPLE (ADA AND NAB) .....51

CHEST X-RAY OR CT .....52

HEMATOLOGY (LOCAL LAB) .....52

CHEMISTRY (LOCAL LAB) .....52

URINALYSIS (LOCAL LAB) .....53

SMOKING HISTORY .....53

SMOKING STATUS CHANGES .....54

INDEX ASTHMA EXACERBATION.....54

INDEX ASTHMA EXACERBATION FOLLOW-UP.....54

SUBSEQUENT ASTHMA EXACERBATION EPISODE .....55

HEALTH CARE RESOURCE UTILIZATION .....56

INJECTION DAY VITAL SIGNS .....56

STUDY DRUG ADMINISTRATION .....56

INJECTION SITE REACTION ASSESSMENT.....57

ACQ-5 ASSESSMENT .....57

MODIFIED BORG DYSPNEA SCALE ASSESSMENT .....57

SPIROMETRY/FeNO/PEAK FLOW.....57

SPIROMETRY/FeNO .....58

END OF TRIAL.....58

INVESTIGATOR SIGNATURES.....59

## Overview

The purpose of the eCRF Completion Guidelines (CCGs) is to provide instructions on how to complete the eCRFs for the CBP-201-206 Connect Biopharma project, whereby Precision for Medicine (Precision) is contracted for data management services. It also provides some general overview information and instructions on how to use the Electronic Data Capture (EDC) used for collecting the participant data for this clinical trial. The EDC training set up for this project should be referenced for further instructions on how to use the database based on the user’s assigned role.

## DM Team Personnel

The primary data management team member(s) for this project are:

**Table 1: DM Team Personnel Information**

Name	Position	Responsibility
Lindsey Falor Precision Email: Lindsey.Falor@precisionformedicine.com	Lead Data Manager (LDM)	Data management activities from database open, conduct, through database lock.
Zachary Kaminski Precision Email: Zachary.Kaminski@precisionformedicine.com	Data Management Oversight (DMO)	Oversee data management activities from database open, conduct, through database lock. May serve as the back-up.

## Medrio

Medrio is the web-based EDC database selected by the Sponsor to collect clinical data for this project. Designated project team members responsible for collecting, cleaning, and/or reviewing the data and project progress will have role-based access to EDC (e.g., CRA, DM, Study Coordinator, PI, etc.).

## Getting Started

### Supported Browsers

This EDC supports all commonly used browsers e.g., Microsoft Edge (formerly Internet Explorer), Firefox (Mozilla), Chrome (Google), Safari (Apple). It is highly recommended that

the latest versions available are used and the browser software is up to date with any vendor updates, especially those concerning security.

**Table 2: Supported Web Browsers**

Browser	Version
Microsoft Edge	9 and later
Firefox (Mozilla)	27 and later
Chrome (Google)	30 and later
Safari	7 and later

## Accessing Your Project

### Study Database

Participant data for this study will be entered into the Medrio EDC application. This application is accessed using a web-based portal called Medrio. You will have access to this portal over the internet using a standard internet browser such as Google Chrome or Firefox. No software needs to be installed locally. The Medrio portal can be found at the following location:

<https://identity.medrio.com/identity/login?signin>.

Below is an example of Medrio login page.

Tip: save the Medrio Internet address as a browser ‘Favorite’ or ‘Bookmark’ to keep it easily accessible throughout the study.

Permissions and project access to the EDC are granted by the Lead Data Manager (LDM) after EDC training is completed by the intended user and a Medrio training certificate has been returned to the LDM.

When access is granted to a project, the user will receive an automated email from “Database System Administrator (Medrio system)” with instructions on how to set up your account and profile. If the LDM has set up permissions and you did not receive the email, check your junk and/or spam email folders in the event it routed there inadvertently. If you still have not received it, contact your CRA who will reach out to the project LDM for access request. The following is an example of the email you will receive:

**[EXTERNAL EMAIL]** DO NOT CLICK links or attachments unless you recognize the sender and know the content is safe.

Welcome to Medrio!

Just so you know, your Medrio account's been granted access to a new study set up by [REDACTED]@precisionformedicine.com.

All you have to do to login is:

- click the link below or copy and paste the address into your browser
- log in using the username below and your existing password

URL: <https://Connect-Asthma-CBP-201-206-Connect-TEST.custom.medrio.com>

USERNAME: [REDACTED]

STUDY: TEST- Connect-Asthma-CBP-201-206

If you have questions about logging in, please contact your study coordinator for further assistance.

Thanks,

The Medrio Team

To access the EDC database, click on the link provided in the email and/or open a web browser and copy paste the link:

<https://Connect-Asthma-CBP-201-206-Connect Biopharma-LIVE.custom.medrio.com>

Enter the username provided in the Welcome to Medrio email.

### First Time Login

Access to Medrio is by invitation only set up by Precision DM. As a new user, you cannot log in until you receive an email and click the link to accept the invitation to join Medrio. If you need access to the study, please contact your CRA to request user activation/invitation from Precision DM. Once Precision DM completes the user activation process, an e-mail invitation will be sent from the following e-mail address: Medrio system, no-reply@mail.medrio.com. You are then redirected to an activation web page where you create your username and password and register as a Medrio user. If the Precision DM has set up permissions and you did not receive the email,

check your junk and/or spam email folders in the event it routed there inadvertently. If you still have not received it, contact the study CRA who will follow-up the issue with the LDM to re-send the invitation email.


Activating your Medrio Account:

1. Open your invitation email.
2. Click the link or copy and paste the address into your browser.
3. Set up your account and choose a password.
  - Passwords must: be at least ten (10) characters in length,
  - contain at least three of the following four items: uppercase letter, one lowercase letter, one character and one number,

Complete all required fields on the activation page. E-learning training needs to be completed (if not completed earlier) before access to the study EDC database can be granted.

Accessing eLearning in Medrio:

- Go to ‘Help’ tab on top left corner of Medrio
- Click on ‘Medrio Community’ from the drop-down option



- Click on ‘Training’ and select ‘Learning Center’ from the drop down
- Select role specific training from Medrio eLearning Home page.
  - Site staff should complete training module “Data Entry – EDC (R41.6)”.



After eLearning is complete, site staff should generate their training certificate (in pdf format) for Medrio training and send it to the Lead Data Manager for access request to EDC and their CRA for filing in the Trial Master File.

### Subsequent Logins

Once you register as a Medrio user, log in by entering your username and password on <https://medrio.com>. You must accept the End User License Agreement (EULA) the first time you log in. All subsequent invitations and assignments appear on your Medrio home page.

### Changing Your Password

To change your password, click on the user’s name at the top right corner of the screen. Click ‘Change Your Password.’ A pop-up window will appear.

A screenshot of a 'Change Your Password' pop-up window. It features three input fields: 'Current Password', 'New Password', and 'Confirm New Password', each with a toggle icon to the right. At the bottom right, there are two buttons: 'Cancel' and 'Change'.

## Password Reset

Users can reset their own passwords by providing answers to security questions they set up upon account creation.

The user password automatically expires after 90 days. Users are notified of the expiration when they log into Medrio and are taken to a page to create a new password. The last two passwords may not be reused when resetting passwords.

## EDC Support / Help

For protocol related questions, please contact your site CRA. For Medrio related questions, please contact the Lead Data Manager, Lindsey Falor: [lindsey.falor@precisionformedicine.com](mailto:lindsey.falor@precisionformedicine.com)

If your study administrator is unable to assist you, please [submit a ticket](#) to Medrio Support.

|Medrio Support | email: [support@medrio.com](mailto:support@medrio.com) | website: <http://medrio.com/contact/contact.html>  
| phone: Toll Free: 877-763-3746

## Site-Level Access

Users are granted access to specific sites and participants based on their role and permissions in the project. If a user has access to only specific sites, then they can only access the forms (eCRFs) and data for the participants who are assigned to those specific sites. If they have permissions to run reports, the report output will only show the results of the participants and sites they have access to view as well.

## Getting More Help

The 'Help' tab at the top right upper corner of the page is available to assist with any questions.


Alternatively, you may contact:

- Your Project Assigned CRA
- Lead Data Manager and Back up DM as noted in the DM Team Personnel section

These links are available on all pages within the database:

- Help for this page – provides help for the page you are currently on
- Documentation – opens a new page, providing access to the Medrio EDC Main User guide
- Medrio Community – opens a new page, providing access to Medrio discussion boards
- Icon Legend – explanation of system and display icons
- System Maintenance – opens a screen providing timing for upcoming scheduled maintenance
- System Requirements – software requirements to use Medrio


- Release Notes – opens a new page, provides information on Medrio release documentation
- Privacy Policy – opens a new page, provides access to the Medrio privacy policy statement
- Contact Us – provides contact information for support



The full list of system icons can be accessed by clicking Icon Legend in the screen shot above.

## Home page

The Home page is the first page a user will see upon login. What appears on the Home page depends upon user permissions and roles. The Home page of a Clinical Research Associate (CRA) is displayed in the example below:



## Creating a New Participant

Participant/Subject IDs will be automatically generated using the Interactive Response Technology (IRT).

Participant data will not be available for entry in EDC until they are enrolled through the IRT.

## Accessing Participants

The 'Home' tab is a portal screen that gives information on Enrolled Subjects, Data Entry, and Queries. You can also access participant data from this screen by selecting the Participant/Subject ID.

Once the ID is selected, you can then begin to 'Enter Data.'

## Enter Data Tab

The 'Enter Data' tab provides a Subject Listing (where you can click on a participant to go into the records for that participant) and 'Tabular' (where you can adjust data entry views). To begin data entry for a CRF, select that form.

To view all participants' data at your site use option 'Site Matrix':

**Site Matrix - Columbus Clinical Services, LLC**

Filter Options 

1 of 1

Locked	Subject	Subject Information	Screening V1a
	12345 [ Create Subject ]	<input type="radio"/>	<input checked="" type="radio"/>
	32476 [ Eligible V1a ]	<input checked="" type="radio"/>	<input checked="" type="radio"/>
	32477 [ Create Subject ]	<input checked="" type="radio"/>	<input checked="" type="radio"/>

Matrix View Icons

Icon	Name	Description
<input checked="" type="radio"/>	Complete Final	In Forms Complete mode: All forms at the visit are in a complete status - either "Complete", "Complete - Final" or combination of "Complete", "Complete-Final" and "Not Expected". In Data Entered mode: All forms at the visit have data entered.
<input checked="" type="radio"/>	Not Expected	All forms for the visit are marked "Not Expected".
<input checked="" type="radio"/>	Partially Complete	In Forms Complete mode: Some forms at the visit have data entered, but not all forms are yet marked complete. In Data Entered mode: Some forms at the visit have data entered.
<input type="radio"/>	Not Entered	In Forms Complete mode: No forms have been marked complete or not expected. In Data Entered mode: No forms at the visit have data entered.

To view data entry status for a particular participant, select option ‘Tabular’:

Home Enter Data Manage Analysis Dashboards

1112223 | Test Site 1 | Entered | Subject Info

**Manage Subject Progress**

+ Forms	Data Entered	Open Queries	Status
- Subject Information			
Informed Consent	✓	▲1	Not Complete
Demographics			Not Complete
Medical and Surgical History			Not Complete
Asthma History and Exacerbation History			Not Complete
Smoking History			Not Complete

To view a participant’s data use option ‘Matrix’:

Home Enter Data Manage Analysis Dashboards

1112223 | Test Site 1 | Entered | Subject Info

**Subject Matrix**


Filter Options

Forms	Subject Information
Visit Date	
Randomization	
Demographics	<input type="checkbox"/>
V1a Follow-Up Phone Log	
Height and Weight	
Physical Exam	
Laboratory Tests	

## Manage Tab

The 'Manage' tab provides Study Management Options and Reports.

The Study Coordinator view is below:



The screenshot shows the Seabreeze eCRF system interface. The top navigation bar includes 'Home', 'Enter Data', 'Manage', 'Analysis', and 'Dashboards'. The 'Manage' tab is selected, showing 'Study Management Options' (Query Listing, Study Documents) and a 'Reports' section. The Reports section is divided into several categories: General Reports (Reports, Advanced Reporting), Ad Hoc Reporting (Browse Data), Data Management (Missing Data, Field Status Report, Scheduled Visits, Coding Report), Monitoring/Approvals (Monitor Summary Report), and Query Metrics (Top Queries Report, Query Aging Report, Query Rate By Site, Query Rate By Form, Query Rate By Field). A note at the bottom states: 'In order for users to access report functionality, both permission(s) assignment and subsequent data refresh are required.'

## General eCRF Entry Guidelines

All requested fields on the eCRF should be completed within 5 business days of each visit. It is best practice to enter data in the order of the eCRF page from top to bottom. This can help avoid missing fields inadvertently. The eCRFs are designed with *skip logic*, meaning that as data is entered on the eCRF in order, subsequent data may grey out to be omitted from data entry. All requested data fields on the eCRF must be completed. Fields with a red asterisk \* are required and must be entered before saving the eCRF.

All information must be entered in English. Attention to correct spelling and accurate information is important. Where appropriate, use clear and concise medical terminology. Do not use abbreviations. The TAB key may be used to advance to the next field. Answer every question as applicable. Do not leave spaces or blank boxes unless specified.

It is important to try to enter all data required on the page and address all queries as they arise. A page will only be saved with a [Complete] status when there are no missing data fields or there are no open queries on the eCRF. A page will reflect the status of Not Complete when the eCRF is partially completed or queries are pending.

## Source Documentation

According to the Food and Drug Administration (FDA) regulations, all data entered on eCRFs must be verifiable in study participants' medical records; therefore, detailed source documentation is required. Source documentation may consist of progress notes, data collection worksheets, laboratory printouts, or additional records from which data are extracted at the study site and entered the eCRF. Each participant's medical record must clearly indicate the date the participant gave his/her consent to participate in the study, including the study number. A dated entry must be made in the participant's medical record for each study visit, and accompanying source documentation must be maintained. Source documentation must be available to the CRA for inspection during monitoring visits to verify eCRF entries.

## Leading Zeroes

If a leading zero is entered for a numeric field, once the page is saved the leading zero will be dropped. For instance, a Systolic Blood Pressure entry of [090] will be saved as [90]. Note for sites in Europe - numbers use a decimal point (.), not a comma (,) to separate the whole number from the fractional number, e.g., 27.6 kg. Use leading zero before decimal if number is lower than 1, e.g., 0.37.

## Radio Buttons

eCRF fields are set up as Radio Buttons, these are designed typically for selecting from a list of choices. It can either be one choice or all that apply. If you would like to remove a selected choice, hold down the *Ctrl* key on your keyboard while clicking the selected value. This will delete the previous choice entered.

## Keyboard Shortcuts

There are two keyboard shortcuts for data entry; Ctrl+S for Save, and Ctrl+N for Save & Next. Buttons with keyboard shortcuts are indicated with an underscore beneath the shortcut letter (see Ctrl+S example below).



## Dates

Complete dates are required on study expect where specified. The date format is DD/MMM/YYYY (e.g. 01/JAN/2025).

Certain date fields for this project have been configured to accept partial dates. These dates are noted within the CCG instructions for those eCRFs.

If part of a date is unknown, the Month and/or Day can be entered as [UN] or [UNK]. A minimum entry of Year is required.

Any date field that is not set up to accept partial dates will fire a query when partial dates are entered. If the year is unknown and nothing is entered, a query will auto-fire. Respond to the query stating no information is known about the desired date.

To enter the date, you may either:

- Utilize the calendar icon next to each date field to select the date you wish to enter, and it will pre-fill the date
- Some date fields have a [Today] shortcut button. If selected, it will enter the current date at time of data entry.

Type the date in the form using DD/MMM/YYYY format.

12345 | Screening V1a | Create Subject | Subject Info

Visit Date Filter

Was the Visit performed?  Yes  No \*

If No, Reason:

Visit Date:

Will subject continue to the next visit?

Mar		2025				
Su	Mo	Tu	We	Th	Fr	Sa
23	24	25	26	27	28	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Today

## Time Format

Times must be entered in a 24-hour clock format (00:00-23:59), see table below for conversions. If the time is unknown and nothing is entered, a query will auto-fire. Please respond to the query stating no information is known about the desired time.

**Table 3: 24-Hour Time Conversion**

AM TIME	24-Hour Time		PM TIME	24-Hour Time
12:00 AM	00:00		12:00 PM	12:00
1:00 AM	01:00		1:00 PM	13:00
2:00 AM	02:00		2:00 PM	14:00
3:00 AM	03:00		3:00 PM	15:00
4:00 AM	04:00		4:00 PM	16:00
5:00 AM	05:00		5:00 PM	17:00
6:00 AM	06:00		6:00 PM	18:00
7:00 AM	07:00		7:00 PM	19:00
8:00 AM	08:00		8:00 PM	20:00
9:00 AM	09:00		9:00 PM	21:00
10:00 AM	10:00		10:00 PM	22:00
11:00 AM	11:00		11:00 PM	23:00

### Log and Repeat eCRFs

Logs are repeat style eCRFs that are typically not tied to a particular visit but can be added and updated as much as needed throughout the course of the project. Adverse Events, Concomitant Procedures and Concomitant Medication are common types of log (repeat) pages. Although these eCRFs are not tied to a particular visit, ensure these pages are up to date throughout the course of the project. If more log eCRFs are needed, you are to create as many repeat forms “pages” as needed for Adverse Events. See the section on Adverse Events for more information.

### Inactivate/Reactivate Loglines

To **delete a record** on a log form if a line was added by mistake:

1. Click the trash can icon on the left of each log line
2. A warning box will appear asking you to confirm the deletion.
3. The record will be removed including the assigned log line identifier.

Concomitant Procedures

Did the subject have any non-drug therapies or procedures during the study?  Yes  No

Row Tools Non-Drug Therapies/Procedures:

1   test

2   test

**Delete Grid Row** [X]

**Warning!**

Are you sure you want to delete this row?

[Cancel](#) [Delete](#)

12345 | [Log Forms](#) | [Create Subject](#) | [Subject Info](#)

Concomitant Procedures

Did the subject have any non-drug therapies or procedures during the study?  Yes  No

Row Tools Non-Drug Therapies/Procedures:

1   test

3   test

NOTE: Once a log line has been deleted, it cannot be retrieved. If deleted in error, you will need to re-enter the data in the eCRF.

### Unscheduled eCRFs

The Unscheduled eCRFs should be used for data collected outside of the regular scheduled study visits per protocol. Select as many eCRFs as needed to capture the assessments performed at the Unscheduled Visit. The following eCRFs are available under the Unscheduled eCRFs Section:

- Unscheduled Visit
  - Enter this CRF first to trigger the applicable data collected within the Unscheduled visit from the below options:
    - 12-Lead ECG (Local Lab)
    - Biomarker Sample
    - Chemistry (Local Lab)
    - Chest X-ray or CT
    - Health Care Resource Utilization
    - Height and Weight
    - Hematology (Local Lab)
    - Immunogenicity Sample (ADA and NAb)
    - Index Asthma Exacerbation Follow-Up
    - Injection Site Reaction (ISR)
    - Laboratory Tests
    - Physical Exam
    - PK Sample
    - Pregnancy Test
    - PRO - ACQ-5
    - PRO - Modified Borg Dyspnea Scale
    - Smoking Status Changes
    - Spirometry/FeNO
    - Subsequent Asthma Exacerbation Episode
    - Urinalysis (Local Lab)
    - Vital Signs

### Other, Specify Fields / Yes/No Questions

Per EDC design, if you enter in an “Other, Specify” comment, but then select a corresponding response field is not “Other,” the data entered in the “Other, Specify” comment field will be removed. Ensure you select the proper choice option before you enter comment text, this will prevent an entry error and inadvertently lose text entered in the other specify comment text field.

The same EDC design also applies to Yes/No and related questions. If you entered the date before you enter the initial yes/no question, then select No, the supporting data you entered will

be removed. As noted in the general eCRF entry guidelines, it is best to enter data in order of the eCRF from top to bottom.

## CRF Book / Visit Map

This EDC is integrated with the Suvoda IRT.

To enter a participant in EDC, the participant must first be registered through the IRT system.

Once a participant is created in IRT, the record will be automatically created in the Medrio EDC. Upon record creation, you will have access to enter data in the Subject Information, Log Forms, and V2 (Visit 2) folders. The IRT will automatically populate the following fields:

- Participant/Subject ID
- Randomization Date
- Randomization Number
- Age At Screening
- Sex
- Kit Number 1:
- Kit Number 2:
- Replacement Kit Number 1A (if applicable)
- Replacement Kit Number 2A (if applicable)
- Replacement Kit Number 1B (if applicable)
- Replacement Kit Number 2B (if applicable)
- Re-screen Participant ID #1 (if applicable)
- Re-screen Participant ID #2 (if applicable)

Manage Subject Progress				
	Forms	Data Entered	Open Queries	Status
[-] Subject Information				
	Informed Consent			Not Complete
	Demographics			Not Complete
	Medical and Surgical History			Not Complete
	Asthma History and Exacerbation History			Not Complete
	Smoking History			Not Complete
[-] End of Trial				
	End of Trial			Not Complete
[-] Log Forms				
	Concomitant Medications			Not Complete
	Concomitant Procedures			Not Complete
	Any Adverse Events?			Not Complete

Enter all required fields on the [Informed Consent] eCRF to trigger the appropriate Screening Channel in the participant's schedule. If V1a is selected for [Screening Channel], the V1a visit folder will populate. If V1b is selected [Screening Channel], the V1a visit will be skipped in the participant's schedule and the V1b visit will appear next.

Enter all Subject Information eCRFs prior to populating data in the Screening V1a or V1b visit. Once a Screening channel is selected, **Unscheduled Visits** will be available for data entry.

Within each participant schedule folder, first populate the [Visit Date] eCRF.

- Once confirmed that the visit occurred, add the [Visit Date:] and the remaining eCRFs for the visit will appear in the participant’s schedule.
- Once confirmed that the participant will proceed to the next visit, the subsequent visit eCRFs will appear in the participant’s schedule.

12345 | Pharmax Research of South Florida, Inc | Create Subject | [Subject Info](#)

Manage Subject Progress				
+	Forms	Data Entered	Open Queries	Status
+ Subject Information				
- Screening V1a				
Visit Date				Not Complete ▾
+ Log Forms				

Manage Subject Progress		
+	Forms	Data Entered
+ Subject Information		
- Screening V1a		
Visit Date	✓	
Eligibility		
Vital Signs		
Height and Weight		
Physical Exam		
Laboratory Tests		
12-Lead ECG (Local Lab)		
Spirometry/FeNO		
V1a Follow-Up Phone Log		
- Screening V1b		
Visit Date		

Due to values being passed from IRT to the EDC, V2 (Visit 2) will be automatically active (with all forms contained within Visit 2, active also) at subject creation. This is to ensure that the IRT system is able to push data entered within the IRT to the EDC without issues due to the target V2 based forms and data points not being active at the time of entry in the IRT system. The V2

[Visit Date] form will function differently than other visits, due to this. If [Was the Visit performed?] is answered as “No” at V2, the forms within this visit will not be inactivated. These forms will need to be addressed and marked as “Not Done” at each where appropriate. If you should need assistance, please contact your CRA to coordinate how to best mark these forms as “Not Done” or a status of “Not Expected”.


Other specific visits have criteria that must be met, in order for that visit to become active for data entry. Below is a table of these criteria.

**Table 4: Specific Visit Activation Criteria**

Activated Visit	Criteria to Trigger Activation
V1a	In the [Informed Consent] form, select V1a for [Screening Channel]
V1b	Channel 1 participants: complete the V1a Visit Date form to activate V1b forms  OR  Channel 2 participants: In the [Informed Consent] form, select V1b for [Screening Channel]
V2	V2 and all forms within this visit, are active when the participant is created.
V3	In the V2 [Index Asthma Exacerbation] form, if [Did the exacerbation result in a hospitalization at V2?] is Yes or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is Yes.  Otherwise V3 will not become active for data entry, and V5 will be the next visit available.
V4	In the V2 [Index Asthma Exacerbation] form, if [Did the exacerbation result in a hospitalization at V2?] is Yes or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is Yes.  Otherwise V4 will not become active for data entry, and V5 will be the next visit available.

Activated Visit	Criteria to Trigger Activation
V9	<p>Both the [Visit Date] and [Eligibility] eCRF forms must be submitted at the Screening V1b visit.</p> <p>This is to support participants that withdraw consent from study visits at any time after V2.</p> <p>If a subject withdraws early and returns for a final visit, complete the V9 forms for this final visit.</p>
End of Trial	<p>Both the [Visit Date] and [Eligibility] eCRF forms must be submitted at the Screening V1b visit.</p> <p>This is to support participants that withdraw consent from study visits at any time after V2.</p>

Figure 1: Visit Flow



To enter Adverse Events, populate the [Any Adverse Events?] eCRF in the Log Forms folder. If yes is selected, the [Adverse Events] eCRF will appear in the folder for entry. If an Adverse Event is indicated as ‘Serious,’ the [Serious Adverse Event] eCRF will populate in this folder for entry.

[-] Log Forms	
Concomitant Medications	
Concomitant Procedures	
Any Adverse Events?	<input checked="" type="checkbox"/>
Adverse Events-1	<input checked="" type="checkbox"/>
Adverse Events (Add new form)	
Serious Adverse Events-1	

In the event a participant has an Unscheduled Visit, navigate to the bottom of the schedule to the [Unscheduled Visit 1] folder. First, populate the [Unscheduled Visit] eCRF to indicate the [Visit Date:] and select all assessments that occurred. These assessments will then populate within the [Unscheduled Visit] folder. In the event an additional Unscheduled Visit is conducted, answer ‘Yes’ to the [Did participant have an additional Unscheduled Visit?] field on the [Unscheduled Visit] eCRF. This will trigger the next Unscheduled visit folder. This study was built to accommodate 10 Unscheduled Visits. In the event additional Unscheduled Visits are needed, contact your study DM.

[-] Unscheduled Visit 1	
Unscheduled Visit	<input checked="" type="checkbox"/>
Vital Signs	
Immunogenicity Sample (ADA and NAb)	
Chest X-ray or CT	
[-] Unscheduled Visit 2	
Unscheduled Visit	

## Queries

Edit checks are programmed within the database to fire queries if the data entered does not satisfy the edit check customized for this project. They are triggered once the eCRF is saved and/or at the time data is entered in a field. The query icon is a red exclamation point that is located next to the data field that needs to be addressed. This is an example of a query on the [Pregnancy Test Collection Date].

12345 | Screening V1a | Eligible V1a | Subject Info

**Pregnancy Test**

Filters Form Tools ⌵ Ⓜ Select All Ⓜ Approve Save Save & Next < >

egnancy Test performed?  Yes  No \* Ⓜ Ⓜ ⌵

If No, Reason:  Ⓜ Ⓜ ⌵

Collection Date: un-unk-unk 31 Ⓜ Ⓜ ⌵ ! Month is required. It cannot be unknown.

Collection Time:  24hr Ⓜ Ⓜ ⌵

Sample:  Serum  Urine Ⓜ Ⓜ ⌵

Result:  Positive Ⓜ Ⓜ ⌵  
 Negative  
 Indeterminate

To review and address a query, open the query that has fired by selecting the Query Icon.

## Resolving Queries

There are three ways to resolve queries:

- 1) Changing the data
  - If data entered is not correct and data should be changed per source, click on the data field, update the data, then select the reason why data is changed. Note: Do not enter data to be updated in the query comments. All data should be updated on the eCRF field.
- 2) Respond to query (No data change)
  - If data is entered correctly, per source, respond to the query by entering a comment to confirm data is correct and/or add additional clarification.
  - Click the [Queries Icon], a field information page will pop up. Select the [Respond] button in the upper right corner, enter a Comment, then select Save. Note: Do not enter data in the query comments. All data should be updated on the eCRF.
- 3) Edit Form
  - If a field and/or form has already been SDV'd and there are queries to resolve post SDV, select [Edit Form] to enable the query to be addressed, select edit options and reason for change, then resolve query – either edit data or respond to query.

## Accessing CCGs

In the 'Manage' tab, under Study Management Options, under Study Documents, you will find the study specific Electronic CRF Completion Guidelines (eCCGs).

## **Project Specific Information**

### **Screen Failures/Enrolled Participants**

Screen failures are defined as participants who signed the ICF to participate in the clinical trial but are not subsequently randomized. These participants are not required to complete the EOT visit assessments. Screen failures should be recorded in the Interactive Response Technology (IRT) according to instructions in the IRT manual.

Participants who initially screen fail for the trial solely due to the ineligible eosinophil count (i.e. Eosinophil count of  $<300$  cells/ $\mu$ L) at Screening Visit 1b, are allowed to re-screen no more than twice if they experience another asthma exacerbation, provided it is deemed appropriate by the Principal Investigator.

If re-screened, the participant should be assigned a new participant number in the IRT.

All participants meeting enrollment criteria will be randomized at baseline (V2) to receive treatment with either rademikibart 600 mg SC or volume-matched placebo.

As participants qualify for randomization, they will be assigned to treatment by the IRT System.

Minimum eCRFs required for Screen Failures include:

- Informed Consent
- Demographics
- Eligibility
- Serious Adverse Events, if applicable
- Adverse Events, if applicable

## **Guidelines -Per Project Specific eCRFs**

### **Visit Date**

Visit date is the date a visit occurred. If [Was the Visit performed?] is Yes, complete [Visit Date] and [Will participant continue to the next visit?]. If assessments for a scheduled visit occur over multiple dates, the date of the first assessment should be recorded.

If the visit was not performed, enter the reason. No further CRFs will populate for that visit. If the participant continues to the next visit, indicating yes for this question will trigger the next visit in the participant schedule to be populated.

### **Informed Consent**

[Participant Number] is an IRT integrated field and is read only.

For [Date Informed Consent Signed], enter the date the participant signed and consented to participate in the study. This date should be before all on-study procedures and dates.

[Informed Consent Version Date] should correspond to the date of informed consent version the participant was consented to.

Select the correct [Screening Channel] to populate the V1a or V1b screening. Screening Channel V1a is for participants who are consented while in a stable state. Screening Channel V1b is for participants who are consented after having experienced a qualifying exacerbation. This field will trigger the V1a or V1b visit in the participant schedule.

For [Was the participant re-consented?], enter Yes if a new consent has been obtained. Populate the Date Informed Re-Consent Signed and Informed Re-Consent Version Date.

The [Participant Re-Screen #1 and #2] are auto generated by IRT in case a participant is re-screened. These fields will be blank if the participant has not been rescreened.

Note: If the participant has been rescreened twice, Participant Re-Screen #1 will be the most recent prior participant number. If the participant has been rescreened once, Participant Re-Screen #1 will be their prior participant number.

## Eligibility

[Protocol Version] should correspond to the protocol version that was effective at the time the participant was consented. Incremental versions should be rounded down to the whole number (i.e., Version 1.1 consented, select Version 1 in EDC).

Note: The following CRFs may not populate based on the protocol version selected.

- Height/Weight
- 12 -Lead ECG
- Pregnancy Test is only required if Pregnancy Test at Baseline Screening V1a and Screening V1b visit are not done on the same date.
- Health Care Utilization

[Screening Timepoint] is required. Ensure this field matches the current visit where Eligibility is confirmed. Participants who enter the study via Channel V1a will have their eligibility confirmed at V1a, V1b, and again at V2.

If response to [Did participant meet all eligibility criteria?] is No, then enter in the data for the Criterion not met.

For criterion number, enter the number listed in protocol sections 7.1 Inclusion Criteria and 7.2 Exclusion Criteria.

The eCRF has pre-defined rows available to enter data for Criterion Not Met. If more rows are needed, select [More Rows] as applicable. If you select 1, then one row will be added to the eCRF, if you select 5 or 10, then that many respective additional rows will be added.

1234571 | Screening V1a | Eligible V1b | Subject Info

### Eligibility

Filters Form Tools

Protocol Version:  \*

Screening Timepoint  V1a  V1b  V2 \*

Did participant meet all eligibility criteria?  Yes  No \*

Row Tools If No, Criterion Not Met:

1

More rows: 1 5 10

Supplemental Screen Failure Reason

The [Supplemental Screen Failure Reason] field is intended for participants who screen fail for reasons other than, or in addition to, inclusion and exclusion criteria. Reasons such as lost to follow-up, withdrawal of consent, and physician decision can be found here.

### **Randomization**

Eligible participants will be randomized to one of the 2 treatment arms using IRT. [Date of Randomization:] and [Randomization Number:] are IRT integrated fields and are read only.

Participants will be randomized at baseline (V2) to received treatment with either rademikibart 600 mg SC or volume-matched placebo.

### **Demographics**

Enter all requested data fields.

[Date of Birth:] the participant must be greater than or equal to 12 years of age to participate in the study and no older than 75 years inclusive at the time of signing the informed consent/assent form. Enter the participant's birth Month (MMM) and year (YYYY). UNK-YYYY may be entered if birth month is unknown or per local regulation.

[Age At Screening]: This is an IRT integration field and is Read-Only. Data will flow from IRT to EDC.

[Sex:] This is an IRT integration field and is Read-Only. Data will flow from IRT to EDC. If Female, please indicate if the participant is of childbearing potential.

[If Female, is participant of childbearing potential?] Indicate if female subject is of childbearing potential. [Yes], will trigger the 'Pregnancy Test' CRF.

[Race (Mark all that apply):] select all race options that are applicable to the participant. If "other" is selected, enter in [Other Race, Specify] field.

The collection of race and ethnicity is based on the FDA Guidance for Industry on the Collection of Race and Ethnicity Data in Clinical Trials. Additional information on this guidance, can be obtained at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical>

### **Medical and Surgical History**

Enter all requested data fields. This CRF is set up as log form. Add 1 row for each medical condition and/or surgery.

The medical history will collect all active conditions and any relevant clinically significant condition which was diagnosed prior to date of Informed Consent/Assent. Record the participant's medical history (excluding Asthma medical history, which is collected in a separate eCRF) including medical conditions, diagnostic results, (drug) allergies and relevant physical examination findings (if applicable). Use standard medical terminology and only record one condition per line.

Any pre-existing condition present at the time the participant signs the ICF through the participant's last visit or 28 days (about 4 weeks) post last dose, whichever is longer, that worsens during the study, should be entered as an adverse event on the Adverse Events eCRF.

Any new medical conditions that occur after signing of the ICF but prior to IP administration should be recorded on the Medical and Surgical History eCRF and considered adverse events. AEs reported during this time that are serious should also be reported as an SAE per protocol Section 11.6.

Any adverse event a participant may experience post signing of ICF that meets the definition of Serious Adverse Events (SAE) per protocol Section 11.7.1 must be reported as an SAE on the SAE eCRF within 24 hours of the Investigator becoming aware of the SAE.

For history and treatment related to asthma, enter data on the 'Asthma History and Exacerbation History' eCRF.

If response to [Does the participant have any past medical conditions/ surgery, excluding Asthma history?] is No, then the rest of eCRF will be disabled for entry.

It is preferred that the complete date is provided as available; however, if the complete [Start Date] and/or [Stop Date] are not known for medical history, then at minimum, enter the Year. For unknown month enter UNK and unknown day enter UN.

**Medical and Surgical History**

Does the participant have any past medical conditions/surgery, excluding Asthma history?  Yes \*  No

Row Tools  Medical History Condition/Event:

Start Date:   Ongoing:  End Date:

More rows: [1](#) [5](#) [10](#)

Ongoing: Select [Ongoing], if the medical history condition is still present at the time the eCRF is being completed. If the medical condition resolves/ends during the course of the study, update the Medical History and enter the End Date.

The eCRF has pre-defined rows available for data entry. If more rows are needed, select [More Rows] at the bottom of the eCRF page as applicable. If you select 1, then one row will be added to the eCRF, if you select 5 or 10, then that many respective additional rows will be added.

**Medical and Surgical History**

Does the participant have any past medical conditions/surgery, excluding Asthma history?  Yes  No \*

Row Tools	Medical History Condition/Event:	Start Date:	Ongoing:	End Date:
1 <input type="checkbox"/>	<input type="text"/>	dd-MMM-yyyy <input type="button" value="31"/>	<input type="checkbox"/>	dd-MMM-yyyy <input type="button" value="31"/>
2 <input type="checkbox"/>	<input type="text"/>	dd-MMM-yyyy <input type="button" value="31"/>	<input type="checkbox"/>	dd-MMM-yyyy <input type="button" value="31"/>
3 <input type="checkbox"/>	<input type="text"/>	dd-MMM-yyyy <input type="button" value="31"/>	<input type="checkbox"/>	dd-MMM-yyyy <input type="button" value="31"/>
4 <input type="checkbox"/>	<input type="text"/>	dd-MMM-yyyy <input type="button" value="31"/>	<input type="checkbox"/>	dd-MMM-yyyy <input type="button" value="31"/>
5 <input type="checkbox"/>	<input type="text"/>	dd-MMM-yyyy <input type="button" value="31"/>	<input type="checkbox"/>	dd-MMM-yyyy <input type="button" value="31"/>
6 <input type="checkbox"/>	<input type="text"/>	dd-MMM-yyyy <input type="button" value="31"/>	<input type="checkbox"/>	dd-MMM-yyyy <input type="button" value="31"/>

More rows: 1 5 10

### Asthma History and Exacerbation History

Record participant's asthma history from the [First appearance of Asthma symptoms date]. For both [First appearance of Asthma symptoms date] and [Asthma Diagnosis Date], year must be known. For unknown month enter UNK and unknown day enter UN.

[Asthma maintenance treatment category at study entry] should be selected from the dropdown menu. If [Other, please specify] is selected, then [Specify Other Asthma maintenance treatment category at study entry] should be completed with the participant's current asthma maintenance treatment.

When [Asthma maintenance treatment category at study entry] is ICS or ICS + LABA or ICS + LABA + LAMA, then [What is the ICS dose level at screening (low, medium, or high dose) as per GINA 2024 Guidelines?] should be completed with appropriate entry from the dropdown list.

[Has the participant been on a stable dose of low-dose maintenance OCS, defined as  $\leq 10$  mg/day of prednisone or equivalent?] is a required field and should be entered before saving the page.

If [Has the participant received any biologic treatment for Asthma, including during a clinical trial?] is yes, add the relevant biologic treatment information to the Prior and Concomitant Medications form. In the field [If yes, add the relevant biologic treatment information to CM-Concomitant Medication Form] enter the CM number only (e.g. 1 or 2).

Record participant's Asthma exacerbation history in the previous 12 months.

[Number of Asthma exacerbations that resulted in hospitalization or ED visit within the previous 12 months prior to screening] Hospitalization includes observation for over 24 hours in an ED or urgent healthcare facility, to collect how many severe Asthma exacerbation in previous 12 months.

For the most recent historical Asthma exacerbation that resulted in systemic corticosteroids treatment and/or hospitalization a complete [Event start date] and [Event end date] are required.

If [Did the exacerbation require treatment with systemic glucocorticosteroids?] is Yes, enter this information on the Concomitant Medications eCRF.

### **V1a Follow-Up Phone Log**

Participants who consent to participate through Screening Channel V1a will be contacted by telephone approximately every 4 weeks after Screening V1a to collect any changes in concomitant medications and any SAEs.

If [Not Done] is selected, the row will be greyed out.

Add "More rows" as needed to complete additional phone contacts with participants.

### **Vital Signs**

Enter all requested data fields. The vital signs assessment per each visit is defined per protocol schedule of events. Ensure the vital signs are collected as per protocol, section 11.2.1. For instructions regarding Injection Day Vital Signs, see the section on Inject Day Vital Signs eCRF.

Any abnormal findings that are new or worsened in severity and clinically significant, in the opinion of the Investigator, will be recorded as an AE.

If response to [Were Vital Signs Collected?] is No, then the rest of eCRF will be disabled for entry. [If No, Reason:] should be completed.

If vital signs were conducted outside of an expected visit per schedule of events, enter the data on the **Unscheduled Vital Signs eCRF**.

If [Not Done] is selected for any parameter, the result field will grey out.

Please enter results in the unit specified on the eCRF.

### **Height/Weight**

Height will only be measured at Screening Visit 1a or 1b. On all subsequent visits select No on [Was Height collected?] question and complete [If No, Reason] field with: Not required. The participants' height must be measured without shoes.

Height will be recorded in centimeters (cm).

Enter unscheduled collections in the **Unscheduled Visit** section.

[Was Weight collected?] If “Yes”, record subject [Weight:] and [Collection Date:].

Note: Weight is defaulted to Kilogram (Kg)

[BMI]: this field is auto- calculated. Once weight and height are both entered click ‘Update Value’ to get the BMI. If weight or height changes value after the page has been saved, click ‘Update Value’ to re-calculate the BMI

Note: BMI will be calculated automatically to 1 decimal place.

### **Physical Exam**

Complete and symptom-directed physical examinations will be performed at timepoints per the Protocol SOA ([Table 5](#)).

A complete physical examination will cover general appearance, dermatology, head, ears, eyes, nose, throat, respiratory, cardiovascular, abdominal, neurological, musculoskeletal, and lymphatic body systems.

Symptom-directed physical examinations can be performed at the Investigator’s discretion at timepoints allowed per the SOA.

Findings from physical examinations will be documented in the appropriate sections of the eCRF. Abnormal findings identified during physical examination will be evaluated and documented by the Investigator as to whether the abnormality is an AE or medical history.

If [Was a Physical Exam performed?] is No, then complete [If No, reason].

Select [Not Required] when symptom-directed physical exam is not conducted per Investigator discretion.

If “Yes”, complete all fields on the form.

Select [Complete] or [Symptom-directed] for the appropriate visit.

The [Date of the Examination] is required and cannot be left Unknown.

For each [Body System] select the appropriate [Interpretation]. The [Finding] field will populate if the Interpretation is indicated as Abnormal Clinically Significant. If Abnormal Clinically Significant, please enter the adverse event or medical history number in the [Finding] field. [Body System Not Assessed] should be utilized for body systems not assessed.

### **Pregnancy Test**

This form will be completed for all female participants recorded as ‘Female’ and if [If Female, is participant of childbearing potential?] is Yes on the Demographics CRF.

A complete [Collection Date:] is required.

Record [Collection Time:] in a 24-hour format.

Record [Sample] as “Serum” or “Urine.” Note that per the Schedule of Assessments, serum pregnancy tests must be conducted at V1a and V1b. A urine pregnancy test must be conducted at V2 (unless V1b and V2 are on the same day), V8, and V9. Both serum and urine pregnancy tests will be analyzed at the local lab.

The Investigator must notify the Sponsor of any pregnancy by completing the Pregnancy Form and emailing it to the Sponsor **within 24 hours** after the Investigator becomes aware of the pregnancy. Email alerts will be disseminated to the Sponsor and safety representatives in the event of an on-study pregnancy.

Pregnancy is not considered to be an AE. Do not report as an SAE unless outcome of pregnancy meets SAE criteria (i.e., ectopic pregnancy, spontaneous abortion includes miscarriage and missed abortion, intrauterine fetal demise, neonatal death, congenital anomaly).

Enter unscheduled collections in the Unscheduled Visit section.

### **Laboratory Test**

Central lab tests for Hematology, Chemistry and Urinalysis sample(s) are collected on this eCRF. Indicate in all sections whether the sample was collected per protocol requirements.

Local lab tests for Hematology, Chemistry and Urinalysis sample(s) are collected on a separate eCRF at V1b.

A complete [Collection Date:] is required.  
Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

Clinically significant abnormal laboratory values should also be entered as an AE. Record the specific diagnosis rather than the abnormal result, see Adverse Events section for additional information.

### **Concomitant Medications**

All medications taken from 3 months prior to the participant's initial Screening Visit 1a or Visit 1b through the end of the trial, including those given in the urgent healthcare setting to treat the index acute asthma exacerbation are captured on this log form.

If systemic steroids were discontinued and later restarted, each course should be entered as a separate entry with its respective start and end dates. This is critical to study endpoints.

Any medication or vaccine (including over the counter or prescription medications, vitamins, and/or herbal supplements) received at Screening visits and throughout the trial must be recorded.

Any biologic drugs taken as treatment for asthma, including during a clinical trial, are to be entered in the Concomitant Medications form.

The [Start Date] and [End Date] allow for Unknown Day and Month. Year is required.

[Ongoing] is only selected in case there is no End Date. Ongoing status of all medications should be assessed at each visit and finally at the End of Trial visit for [End Date:] information.

If [Unit] or [Dose Form] or [Route] or [Frequency] or [Prophylaxis, Specify] is "Other" complete the [Other, Specify] field accordingly.

If [Frequency] is pro re nata (PRN) and the medication is related to asthma treatment, please enter approximate actual frequency instead of selecting PRN. When the frequency changes, add a new entry to capture the intensification or reduction in pharmacological treatment.

Note: the exception to the above is PRN rescue medication changes in frequency. This information will be reported by participants in the daily e-Diary. PRN rescue medication use should only be captured once in the Concomitant Medications eCRF.

Depending on the selection for [Indication], populate the remaining fields. Select all that apply

- Medical History: Refer to the Medical History (MH) eCRF for the corresponding MH and enter the MH number. If medication is related to MH and is ongoing at the time of ICF. Leave End Date blank and check “ongoing.” The medication will not need to be entered again for the duration of the study.
  - Note: If the medication is related to historical asthma exacerbations, do not select this value; rather select the “Asthma” option noted below.
- Asthma: Select asthma if medication is for treatment of asthma.
  - Note: For medications related to historical asthma exacerbations, select this value for [Indication].
- Asthma Exacerbation: Check either Index or Subsequent for the question ‘Is exacerbation an index or subsequent exacerbation?’ If medication is for a subsequent asthma exacerbation, please provide the associated Subsequent Exacerbation number.
  - Note: If the medication is related to historical asthma exacerbations, do not select this value; rather select the “Asthma” option above.
- Adverse Event: Select if medication is for treatment of an adverse event. Refer to the Adverse Event (AE) eCRF for the corresponding AE number.
- Procedures: Select Procedures if medication is used for a procedure or following a procedure. Refer to the Concomitant Procedures eCRF for the corresponding Procedure number.
- Prophylaxis: Select if medication is used for prophylaxis of any condition. Please provide details on the type of prophylaxis taken by the participant.
- “Other” is *only* to be used if the reason for administration is *not* an Adverse Event, Medical History, asthma, asthma exacerbation, or Prophylaxis e.g., because the medication has no specific therapeutic indication (e.g., nutritional supplements). Please use this option and make your description as specific as possible.

Select [More rows] to add rows to this log form.

The Medical Monitor should be contacted if there are any questions regarding prior or concomitant medication or procedures.

### Concomitant Procedures

[Non-Drug Therapies/Procedures]: Provide the procedure or non-medication the treatment name. Enter one term per line. Examples of non-drug therapies/procedures include but are not limited to invasive/non-invasive ventilation (Continuous Positive Airway Pressure [CPAP], Bilevel Positive Airway Pressure [BiPAP]), endotracheal intubation, bronchial thermoplasty, and arterial blood gas (ABG) analysis.

If ventilation was administered during asthma exacerbation episodes (Index or Subsequent), please record it in the Concomitant Procedure eCRF.

If [Did the participant have any non-drug therapies or procedures during the study?] is Yes, the form will generate fields to complete.

The [Start Date] and [End Date] allow for Unknown Day and Month. Year is required.

[Ongoing] is only selected in case there is no End Date. Ongoing status of all therapies should be assessed at each visit and finally at the End of Trial visit for [End Date:] information.

If [Frequency] is “Other, Specify,” complete [Specify Other Frequency].

Depending on the selection for [Indication], populate the remaining fields. Select all that apply.

- Medical History: Refer to the Medical History (MH) eCRF for the corresponding MH and enter the MH number. If medication is related to MH and is ongoing at the time of ICF leave End Date blank and check “ongoing.” The medication will not need to be entered again for the duration of the study.
- Asthma: Select asthma if medication is for treatment of asthma.
- Asthma Exacerbation: Check either Index or Subsequent for the question ‘Is exacerbation an index or subsequent exacerbation?’ If medication is for a subsequent asthma exacerbation, please provide the associated Subsequent Exacerbation number.
- Adverse Event: Select if medication is for treatment of an adverse event. Refer to the Adverse Event (AE) eCRF for the corresponding AE number.
- Procedures: Select Procedures if medication is used for a procedure or following a procedure. Refer to the Concomitant Procedures eCRF for the corresponding Procedure number.
- Prophylaxis: Select if medication is used for prophylaxis of any condition. Please provide details on the type of prophylaxis taken by the participant.
- “Other” is *only* to be used if the reason for administration is *not* an Adverse Event, Medical History, asthma, asthma exacerbation, or Prophylaxis e.g., because the medication has no specific therapeutic indication (e.g., nutritional supplements). Please use this option and make your description as specific as possible.

Select [More rows] to add rows to this log form.

The Medical Monitor should be contacted if there are any questions regarding prior or concomitant medication or procedures.

### **Any Adverse Events?**

All AEs regardless of causality will be recorded. If [Has the participant experienced any Adverse Events?] is Yes and the eCRF is saved, the Adverse Events eCRF will populate to collect further information.

## Adverse Events

This form is completed if the participant has experienced any Adverse Events. To add a new “Adverse Events” form, select “Adverse Events (add new form) from the Form View within the Log Forms folder.

[AE #]: This field should be unique and sequentially assigned. This is a manual field. Please check prior AE # added to assist with consistent numbering. This field will be utilized to reference AE as an Indication across other CRFs like Concomitant Medications/Procedures, Exacerbation History, etc.

[AETERM]: List only one adverse event per log line. This field will be coded using the information provided verbatim.

- Record the specific diagnosis rather than abnormal results, e.g., “ALT 120 U/L” is not allowed.
- Record only one term per row, e.g., the subject happened “Nausea and Vomiting,” should be provided as “Nausea” and “Vomiting” separately.
- Do not use abbreviations, e.g., GERD should be spelled out as Gastroesophageal reflux disease.
- Please do not enter the Medications or Non-drug Treatments.
- If a pre-existing medical condition from the Medical History CRF worsens or increases in severity, record this change in condition as an Adverse Event. Use the same event term that was recorded in the Medical History CRF and modify it to note worsening.
- Avoid recording duplicated AEs if an ongoing AE or MH has already been entered.
- If applicable, organ or body part/system involved should be specified to allow for accurate coding. For example: “Neck Pain” and “Abdominal Pain.”
- Do not record “pregnancy” as an Adverse Event.

[Start Date] and [End Date] must be a complete date. Partial dates are not acceptable. If an AE is serious, indicate the dates the AE becomes/is considered serious on the SAE CRF separately. Partial dates are not acceptable.

[Ongoing] is only selected in case there is no End Date. Ongoing status of all AEs should be assessed at each visit and finally at the End of Trial visit for [End Date:] information. In the event a participant passes away on study, the date of death should be entered as the [End Date:] for all ongoing AEs

Select the appropriate [AE Category (Select all that apply)], this is a required field. “Not Applicable” should be selected in the event none of the categories apply.

## [DILI] Suspected Drug-induced Liver Injury (DILI)

DILI refers to a liver injury induced by various chemical drugs, biological products, herbal medicines and their metabolites or even excipients. Hy's Law can facilitate assessment of severe

liver injury predominated by hepatocellular injury. It specifically refers to cases that meet all the following 3 criteria:

For participants with normal liver function tests at baseline:

1. ALT or AST  $\geq 3 \times$  ULN during Treatment Assessment Period, and
2. Total bilirubin  $> 2 \times$  ULN during Treatment Assessment Period; without cholestasis at baseline (serum alkaline phosphatase [ALP] increased), and
3. No other identifiable causes explaining the simultaneous elevation of aminotransferases and total bilirubin, such as viral hepatitis A, B, C or E or other acute liver diseases, or concomitant use of other drugs that may induce liver injury.

#### [AESI] Adverse Event of Special Interest (AESI)

An AESI may be serious or non-serious and be of scientific and medical concern specific to the Sponsor's product mechanism of action, for which ongoing monitoring may be appropriate. Such an event might warrant further investigation to characterize and understand it and rapid communication by the trial Sponsor to other regulatory authorities may also be warranted.

For this trial, AESIs shall include:

- Conjunctivitis
- Keratitis
- Severe injection site reactions persisting for more than 24 hours: defined as injection site reactions persisting for more than 24 hours and the severity is CTCAE Grade  $\geq 3$ .
- Parasitic and opportunistic infections: whether the infection is classified as opportunistic infection will be determined after discussion with the medical monitor. When reporting opportunistic infection, the Investigators will refer to protocol Appendix J Table 7.
- Anaphylaxis: defined according to the symptoms shown in protocol Appendix J Table 8.

#### [UADE] Unanticipated Adverse Device Effect (UADE)

According to 21 CFR 812.3(s), a UADE means any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device (pre-filled syringe in this case), if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of participants.

[Severity] is important to distinguish between serious and severe AEs. The Investigator will use the CTCAE Version 5.0 to assist in the determination of severity and clinical significance. The following represents CTCAE grading of AE severity:

- Grade 1: asymptomatic or mild symptoms or clinical or diagnostic observations only or intervention not indicated.
- Grade 2: minimal, local, or noninvasive intervention indicated or limiting age-appropriate instrumental activities of daily living (ADL). Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

- Grade 3: hospitalization or prolongation of hospitalization indicated or disabling or limiting self-care ADLs. Self-care ADLs refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications and not bedridden.
- Grade 4: Life-threatening consequences with urgent intervention indicated.
- Grade 5: Death related to AE.

[Serious] An AE or suspected adverse reaction is considered “serious” if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes:

- Death
- A life-threatening AE (i.e., presented an immediate risk of death from the event as it occurred. This criterion is not intended to include an AE that, had it occurred in a more severe form, might have caused death.)
- Inpatient hospitalization or prolongation of existing hospitalization
- A persistent or significant incapacity to conduct normal life functions
- A congenital anomaly/birth defect
- Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

The following events do not meet the definition of an SAE: hospitalization for elective treatment of a pre-existing condition that does not worsen from baseline, hospitalizations for a standard procedure for IP administration, routine monitoring of the studied indication not associated with any deterioration in condition, social or convenience admission to a hospital, prolongation of a hospitalization for social or convenience reasons not associated with the occurrence of an AE, or hospitalization or an emergency room visit that lasts less than 24 hours that does not meet the criteria of an important medical or a life-threatening event.

If [Serious:] is selected as Yes, the Serious Adverse Event eCRF will populate for entry in the Log Forms Subject Information folder to collect additional details.

Email alerts will be disseminated to the Sponsor and safety representatives when [Serious:] is selected as Yes.

[Serious Adverse Event #:] This field should be unique and sequentially assigned. This is a manual field. Please check prior SAE # added to assist with consistent numbering. This SAE # should match the number entered in the SAE CRF.

[Causality] relates to the IP administration according to the following guidelines:

- Possibly Related: the AE is known to occur with the IP, there is a reasonable possibility that the IP caused the AE, or there is a temporal relationship between IP and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the IP and the AE.
- Unlikely Related: there is not a reasonable possibility that the administration of the IP caused the event, there is no temporal relationship between the IP and event onset, or an alternate etiology has been established.

[Action Taken with Study Drug:] Select ‘Dose not changed’ if full dose of study drug was already administered. Select ‘Dose Interrupted’ if AE resulted in interruption of full dose during administration. Select ‘Not Applicable’ if AE occurs prior to dosing.

[Outcome] Select outcome of the AE from the drop-down list: Resolved, Resolved with Sequelae, Not Resolved, Unknown, and Death. In the event a participant passes away on study, only the AE that is the primary reason for death should have an outcome of ‘Death’ and other AE in this case should be ‘Not Resolved’.

### **Serious Adverse Events**

This form will be completed if [Serious] is Yes on the “Adverse Events” eCRF. Complete the SAE eCRF within 24 hours of awareness.

Only enter one SAE per eCRF, add a new instance of the SAE eCRF for additional SAEs.

Enter the [AE#] that correspond to the event term reported from the “Adverse Events” eCRF.

[SAE #]: This field should be unique and sequentially assigned. This is a manual field. Please check prior SAE # added to assist with consistent numbering.

Mark all that apply when selecting the [Serious Criteria Met].

If the participant is hospitalized, complete the [Date of Inpatient Hospitalization] and [Date of Inpatient Hospitalization Discharge], partial dates are not acceptable.

Note: If the SAE criteria are prolongation of existing hospitalization, then [Date of Inpatient Hospitalization] refers to the day when the inpatient must prolong the hospitalization due to SAE.

If the participant has a fatal outcome, complete if the redacted autopsy report has been uploaded or emailed to: [connectsafety.sm@thermofisher.com](mailto:connectsafety.sm@thermofisher.com) and [PV@connectpharm.com](mailto:PV@connectpharm.com).

[Date of First Dose of Study Drug:] is a derived field, populating from the Study Drug Administration eCRF.

Any updates saved to the SAE (or it's supporting parent AE) eCRF will result in an email alert to the Safety and Sponsor representatives.

To add a new "Serious Adverse Events" form, select the "Serious Adverse Events (add new form)" from the Forms View.

### **Treatment Failure**

This form becomes active for data entry when a participant is noted as having been randomized (On the [Randomization] form, [Was participant randomized?] = "Yes").

The purpose of this form is to capture information pertaining to possible treatment failure during the trial. Treatment failure is defined as death due to any cause, (re)admission to a hospital for asthma, ED (re)visit or unscheduled medical visit for worsening of asthma symptoms, or the necessity to intensify pharmacologic treatment (including second course of systemic steroids for asthma exacerbation).

The first data point asks to confirm if any of the following occurred after randomization or study drug administration, and prior to the End of Trial. Mark all that apply to the participant or mark "None of the Following" if none occurred prior to the End of Trial.

- None of the Following
- Death due to any cause
- Admission or re-admission to a hospital for asthma (not including hospitalization at V2 if participant was hospitalized for the index exacerbation)
- Visit or re-visit to an emergency department for worsening of asthma symptoms (not including emergency department visit at V2 if participant had an emergency department visit for the index exacerbation)
- Unscheduled medical visit for worsening of asthma symptoms (not including any unscheduled medical visit at V2)
- Necessity to intensify pharmacologic treatment after treatment initiated at V2 (including second course of systemic corticosteroids)

These events exclude any hospitalization, emergency department visit, unscheduled medical visits and treatment initiation at V2.

If "None of the Following" is selected, no other choices are to be selected (As an exclusive option). If another option is also selected, a query is generated requesting that the choice selections be corrected.

If "Death due to any cause" is selected, please ensure that the cause of death is entered into the EDC on the Adverse Event form with the outcome of death, as well as having an associated complete SAE form.

For the other choice selections, a date field will become active to capture information pertaining to the first date this event occurred (not including V2).

The date provided for each treatment failure field should have a corresponding date also entered in a follow-up or subsequent exacerbation EDC form, within the appropriate section (hospitalization, emergency department visit, etc.).

As the participant continues within the study, please update this form as needed if they experience any of the listed events.

**Table 5: Treatment Failure Follow-up Date Entry Guidance**

Event	Date Entry	Additional Guidance/Requirements
Admission or re-admission to a hospital for asthma (not including hospitalization at V2 if participant was hospitalized for the index exacerbation)	First date of hospitalization, not including hospitalization that may have occurred at Visit 2	<p>Also indicate a worsening (admission or re-admission to the hospital after V2) of the index exacerbation on the <b>Index Asthma Exacerbation Follow-up</b> form or new exacerbation on the <b>Subsequent Asthma Exacerbation Episode</b> form and indicate if there was intensification of pharmacologic treatment for the worsening of symptoms. Also, mark that intensification of pharmacologic treatment occurred on this <b>Treatment Failure</b> form.</p> <p>Note: Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Courses of corticosteroids separated by 7 days or more should be treated as separate acute exacerbations.</p> <p>Ensure that the start date of the hospital admission on this form matches the start date on the Index Asthma Exacerbation Follow-up form or the Subsequent Asthma Exacerbation Episode form.</p> <p>Record as an <b>Adverse Event</b> if the exacerbation meets the definition of more severe and more frequent than expected than the index exacerbation.</p> <p>Note: Generally, this meets the definition of a <b>Serious Adverse Event</b>.</p>
Visit or re-visit to an emergency department for worsening of asthma symptoms (not including emergency department visit at V2 if participant had an emergency department visit for the index exacerbation)	First date of emergency department visit not including emergency department visit that may have occurred at Visit 2	<p>Enter a worsening (visit or re-visit to an emergency department after V2) of the index exacerbation on the <b>Index Asthma Exacerbation Follow-up</b> form or new exacerbation on the <b>Subsequent Asthma Exacerbation Episode</b> form and indicate if there was intensification of pharmacologic treatment for the worsening of symptoms.</p> <p>Note: Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Courses of corticosteroids separated by 7 days or more should be treated as separate acute exacerbations.</p> <p>Ensure that the start date of the emergency department visit on this form matches the start date on the Index Asthma Exacerbation Follow-up form or the Subsequent Asthma Exacerbation Episode form.</p> <p>Record as an <b>Adverse Event</b> if the exacerbation meets the definition of more severe and more frequent than expected than the index exacerbation.</p> <p>Note: Generally, this meets the definition of a <b>Serious Adverse Event</b> if the emergency department visit lasted more than 24 hours.</p>
Unscheduled medical visit for worsening of asthma symptoms (not including any unscheduled medical visit at V2)	First date of unscheduled medical visit for worsening of asthma symptoms	<p>Enter a worsening (unscheduled medical visit after V2) of the index exacerbation on the <b>Index Asthma Exacerbation Follow-up</b> form or new exacerbation on the <b>Subsequent Asthma Exacerbation Episode</b> form and indicate if there was intensification of pharmacologic treatment for the worsening of symptoms.</p>

		<p>Be sure to enter any changes in the <b>Concomitant Medications</b> when these Unscheduled Medical Visits occur.</p>
<p>Necessity to intensify pharmacologic treatment after treatment initiated at V2 (including second course of systemic corticosteroids)</p>	<p>First date of intensification of pharmacologic treatment</p>	<p>Intensification of pharmacologic treatment after initial treatment at V2 can include: a second course of corticosteroids, increasing the duration of treatment beyond the initial course (eg, 5 days), adding a new medication, or increasing the dose for an asthma exacerbation.</p> <p>Enter 1 or more new courses of treatment (eg, second course of corticosteroids) for the index exacerbation or a subsequent exacerbation as new row(s) on the <b>Concomitant Medication</b> form.</p> <p>Ensure that the start date of the intensification of pharmacologic treatment on this form matches the start date on the Concomitant Medication form.</p> <p>If the treatment is for the index exacerbation, check the box on the <b>Index Asthma Exacerbation Follow-up</b> form for the Intensification of Pharmacologic Treatment.</p> <p>If the treatment is for a new exacerbation, mark the Exacerbation Treatments that apply on the <b>Subsequent Asthma Exacerbation Episode</b> form.</p>

### **12-Lead ECG (Local Lab)**

Measurements will be performed with the participant resting in a supine position for approximately 5 minutes before each reading and should be carried out after measurement of vital signs and before spirometry. ECGs should be performed before blood is drawn during visits requiring blood draws.

If [Was a 12-Lead ECG performed?] is Yes, complete all fields on the form. [Date Performed] may not be Unknown.

Record the protocol defined assessments in the specified units.

The [QTcF] field is auto calculated. Once [RR interval] and [QT interval] are both entered, click 'Update Value' to get the QTcF. If either of these variables change, click 'Update Value' again to re-calculate the QTcF.

Note: RR interval field length will accept 4 digits result values.

If [Interpretation] is indicated as Abnormal, enter the associated Adverse Event number or Medical History Number in the [If Abnormal, Specify:] field, as applicable.

Enter unscheduled collections in the Unscheduled Visit section.

### **PK Sample**

If [Were PK sample(s) collected] is Yes, complete the [Collection Date] and [Collection Time].

A complete [Collection Date:] is required.

Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

### **Biomarker Sample**

If [Were biomarker sample(s) collected?] is Yes, complete the [Collection Date] and [Collection Time].

A complete [Collection Date:] is required.

Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

### **Immunogenicity Sample (ADA and NAb)**

If [Were Immunogenicity (ADA and NAb) sample(s) collected?] is Yes, complete the [Collection Date] and [Collection Time].

A complete [Collection Date:] is required.  
Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

### **Chest X-ray or CT**

A chest X-ray (or CT scan), for purposes of determining participant eligibility, will be performed only at Screening Visit 1b if no chest imaging (X-ray or CT) is available within the previous year or if clinically indicated.

[Was the chest X-ray/CT performed on this visit?] Enter yes if performed. Enter no if a historical (within 12 months) chest imaging is available or if not done.

If utilizing a historic (within 12 months) chest X-ray or CT scan, enter “Historical (within 12 months) chest X-ray/CT available” in the field [If No, Reason:].

Enter [Date Performed] for the date the chest X-ray or CT scan was performed. This date may be the same as the visit date, or within the past 12 months.

Additional information is requested when [Interpretation:] is Abnormal.

Enter unscheduled collections in the Unscheduled Visit section.

### **Hematology (Local Lab)**

Local Labs will be collected during Screening Visit 1b to expedite eligibility. At other visits, labs will be collected centrally on the “Laboratory Test” eCRF.

Enter the results in the corresponding units available. Note that you will need to manually enter the lab normal ranges.

[If abnormal, clinically significant?] should be entered for all analytes that were tested and a result received. If the value was not abnormal, please select “No”. If the value is not within normal reference ranges, please select “Yes” if clinically significant, or “No” if not clinically significant.

Enter unscheduled collections in the Unscheduled Visit section.

### **Chemistry (Local Lab)**

Local Labs will be collected during Screening Visit 1b to expedite eligibility. At other visits, labs will be collected centrally on the “Laboratory Test” eCRF.

Enter the results in the corresponding units available. Note that you will need to manually enter the lab normal ranges.

[If abnormal, clinically significant?] should be entered for all analytes that were tested and a result received. If the value was not abnormal, please select “No”. If the value is not within normal reference ranges, please select “Yes” if clinically significant, or “No” if not clinically significant.

Enter unscheduled collections in the Unscheduled Visit section.

### **Urinalysis (Local Lab)**

Local Labs will be collected during Screening Visit 1b to expedite eligibility. At other visits, labs will be collected centrally on the “Laboratory Test” eCRF.

Enter the results in the corresponding units available. Note that you will need to manually enter the lab normal ranges.

Enter unscheduled collections in the Unscheduled Visit section.

### **Smoking History**

If [Was the Smoking History collected?] is Yes, complete the [Assessment Date].

[What is the participant’s Smoking History?] Former smokers are defined as individuals who have stopped smoking for at least 6 months prior to Screening (Visit 1b).

Note: This field is not IRT integrated at V1b, and sites should select applicable options in Medrio.

[Approximate Smoking Start Date] and [Approximate Smoking Cessation Date] will allow an Unknown entry for Day and Month. The Year is required. Use the format UN-UNK-YYYY for unknown day and month. Use the format UN-MMM-YYYY for unknown day. If the participant is a non-smoker, leave these fields blank.

[Estimated Number of Pack-Years] should be calculated as defined in Protocol Section 11.1.2. Number of pack years = ((number of cigarettes per day / 20) × number of years smoked) (e.g., 20 cigarettes per day for 10 years, and 10 cigarettes per day for 20 years both equal 10 pack-years). If participant is a non-smoker, enter 0 pack-years.

One pack of cigarettes a day for 1 year is equivalent to:

- 1 cigar or pipe per day for 1 year
- Smoked hookah or shisha =1 session per day for 1 year

- Vaped e-cigarettes =0.5 mL e-liquid per day for 1 year, or =1 cartridge/tank/pod per day for 1 year
- 1 use of marijuana per day for 1 year

[Smoking Method (Select all that apply)]: If participant is a non-smoker, leave this field blank. Otherwise, select all that apply.

### **Smoking Status Changes**

Changes in smoking status are captured for consented participants through EOT visit. Pharmacological smoking cessation therapies will be recorded on Concomitant Medication eCRF.

[Smoking Start Date] and [Smoking Cessation Date] allow for Unknown day. Month and Year are required. Use the format UN-MMM-YYYY for unknown day.

Enter unscheduled collections in the Unscheduled Visit section.

### **Index Asthma Exacerbation**

This eCRF indicates the baseline exacerbation of the participant at the V2 visit.

Complete dates are required throughout the eCRF.

Times are to be reported in 24-hour format.

[Did the exacerbation result in a hospitalization at V2?] Based on the response to this question, the participants' schedule will trigger visits V3 and V4, or it will skip these visits and populate next the V5 visit. If [Did the exacerbation result in a hospitalization at V2?] is Yes or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is Yes, then visits V3 and V4 will appear in the participant's schedule. If [Did the exacerbation result in a hospitalization at V2?] is No or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is No, then V3 and V4 will be skipped and the V5 visit will appear in the participant's schedule.

If ventilation was administered, please record it in the Concomitant Procedure eCRF.

In the event the Index Asthma Exacerbation requires hospitalizations/interventions which are ongoing beyond the V2 visit, the exacerbation information should be followed to completion and entered on the 'Index Asthma Exacerbation Follow-Up' eCRF.

### **Index Asthma Exacerbation Follow-Up**

This eCRF is utilized to follow any hospitalizations/interventions which were ongoing from the V2 'Index asthma Exacerbation' eCRF or to capture any new treatment visits related to the index (qualifying) exacerbation.

Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Courses of corticosteroids separated by 7 days or more should be treated as separate acute exacerbations.

Complete dates are required throughout the eCRF.  
Times are to be reported in 24 hr. format.

All Urgent Care, Emergency Room, Hospitalization, and ICU details are to be entered in the CRF, as applicable.

[Did the exacerbation result in an Urgent Care (re)visit?]: Mark YES if after V2, the participant visited an urgent care for the index exacerbation for the first time or had a second urgent care visit (revisit) due to the ongoing index exacerbation.

[Did the exacerbation result in an ER (re)visit?]: Mark YES only if after V2, the participant visited the emergency department for the index exacerbation for the first time or had a second emergency department visit (revisit) due to the ongoing index exacerbation.

[Did the index exacerbation require (re)hospitalization?]: Mark YES only if after V2, the participant was admitted to the hospital for the index exacerbation for the first time or had a second admission (readmission) due to the ongoing index exacerbation.

If ventilation was administered, please record it in the Concomitant Procedure eCRF.

An Unscheduled Visit may be utilized to complete this form as needed.

### **Subsequent Asthma Exacerbation Episode**

Enter 1 eCRF for each subsequent Asthma Exacerbation Episode after the Index Asthma Exacerbation resolves.

Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Courses of corticosteroids separated by 7 days or more should be treated as separate acute exacerbations. The subsequent exacerbation CRF appears starting on Visit 6 (Day 7).

[Episode #] This field should be unique and sequentially assigned. This is a manual field. Please check prior subsequent asthma exacerbation episode # added to assist with consistent numbering.

Note: The index asthma exacerbation should not be counted. Please count starting from the first subsequent asthma exacerbation.

Complete dates are required throughout the eCRF.

Times are to be reported in 24 hr. format.

All Urgent Care, Emergency Room, Hospitalization, and ICU details are to be entered in the CRF, as applicable.

If ventilation was administered, please record it in the Concomitant Procedure eCRF.

Complete the SAE CRF if the exacerbation meets SAE criteria.

An Unscheduled Visit may be utilized to complete this form as needed.

### **Health Care Resource Utilization**

Complete dates are required throughout the eCRF.

Times are to be reported in 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

### **Injection Day Vital Signs**

Utilize this eCRF to record Vital signs requirements at the V2 visit.

Enter all requested data fields. Injection day vital signs are to be collected at timepoints specified in protocol section 11.2.1. Fields are available in the eCRF for any other timepoints that may be collected.

Any abnormal findings that are new or worsened in severity and clinically significant, in the opinion of the Investigator, will be recorded as an AE.

If response to [Were Vital Signs Collected?] is No, then the rest of eCRF will be disabled for entry. [If No, Reason:] should be completed.

If [Not Done] is selected for any parameter, the result field will grey out. Please enter results in the unit specified on the eCRF.

### **Study Drug Administration**

Utilize this eCRF to record information relating to IP Administration at the V2 visit.

The following fields on this eCRF are IRT integrated and are read only. If a kit is not replaced, the replacement fields will appear blank.

[Kit Number 1:]

[Kit Number 2:]

[Replacement Kit Number 1A:]

[Replacement Kit Number 2A:]

[Replacement Kit Number 1B:]

[Replacement Kit Number 2B:]

A complete [Date Administered:] is required.  
Record [Start Time of Injection:] and [End Time of Injection:] in a 24-hour format.

[Start Time of Injection:] should indicate the time the first injection began.  
[End Time of Injection:] should indicate the time the last injection was completed.

If a participant does not receive all four injections, indicate 'Not Done' in the corresponding [Anatomical Location:] field which correlates with doses not received.

### **Injection Site Reaction Assessment**

For assessments conducted at V2, record injection site reaction assessment at 30 minutes post-injection and 2 hours post-injection using the drop-down options available for [Timepoint].

For assessments conducted after V2, select 'Not applicable' for the [Timepoint] field. Only one timepoint needs to be completed. The other row may be left blank.

A complete [Collection Date:] is required.  
Record [Collection Time:] in a 24-hour format.

Report clinically significant findings on the Adverse Event eCRF.

Enter unscheduled collections in the Unscheduled Visit section.

### **ACQ-5 Assessment**

A complete [Completion Date:] is required.

### **Modified Borg Dyspnea Scale Assessment**

A complete [Collection Date:] is required.  
Record [Collection Time:] in a 24-hour format.

### **Spirometry/FeNO/Peak Flow**

This eCRF is only available in the V1b visit schedule.

If [Was the Spirometry assessment completed?] is No, complete [If No, Reason].

If [Was the Peak Exploratory Flow assessment completed?] is required.

If [Was the Peak Exploratory Flow assessment completed?] is Yes, complete the [Timepoint], [Collection Date:] and [Collection Time:].  
A complete [Collection Date:] is required.

Record [Collection Time:] in a 24-hour format.

If [Was the FeNo assessment completed] is No, complete [If No, Reason].

If “Yes”, complete the [Collection Date] and [Collection Time].

Note: in the event a FeNo assessment is Not Required at the time of Spirometry Assessment, select ‘Not Required’ for this section. See Protocol Schedule of Assessments.

### **Spirometry/FeNO**

If [Was the Spirometry assessment completed?] is No, complete [If No, Reason].

If “Yes”, complete the [Timepoint], [Collection Date:] and [Collection Time:].

A complete [Collection Date:] is required.

Record [Collection Time:] in a 24-hour format.

Enter one row for each spirometry session. For example, the pre-BD session should be entered as one line, and the post-BD session should be entered as one line.

There are more rows than required per protocol in case of unscheduled sessions. Mark No to [Was the Spirometry assessment completed] for unnecessary rows. [If No, Reason] can indicate “Not required per protocol” or similar text.

If [Was the FeNO assessment completed] is No, complete [If No, Reason]. If “Yes”, complete the [Collection Date and Time].

Note: in the event a FeNO assessment is Not Required at the time of Spirometry Assessment, select ‘Not Required’ for this section. See Protocol Schedule of Assessments.

Enter unscheduled collections in the Unscheduled Visit section.

### **End of Trial**

This eCRF is required for all participants who received IP administration on V2.

A complete date is required for [Date of Trial Completion/Termination:]. In the event a patient passes away after V2 visit, populate the date of death in this field.

If [Reason for Trial Completion/Termination:] is Adverse Event, ensure this information is entered on the corresponding AE eCRF.

If [Reason for Trial Completion/Termination:] is Death, ensure all ongoing log form entries are updated with an [End Date:] consistent with the date of death.

If [Death Details:] is checked as ‘Not Due to Asthma,’ add details on cause of death in [Specify Cause of Death:]

### **Investigator Signatures**

Principal Investigators are required to review and apply an electronic signature for each participant’s CRF. Applying this signature is the Investigator’s attestation that the data entered in the database is complete and accurate. The CRA informs the Investigator when the CRFs are ready for review and signature. This notification occurs after the CRFs have been cleaned, verified against the source documents, and frozen. Investigators may be informed to sign eCRFs prior to freezing the database. Re-signing may be required if eCRFs have been updated due to new information or query response.

The Investigator Signature may be applied to an individual form, or the Investigator may batch sign the entire casebook.

To Sign an individual form, navigate to that form, and review the data entered. At the bottom of the form, click on the Sign button to apply your credentials. A popup window will appear. Add your username and password. You will see that your signature has been applied.

To Batch sign a participant’s casebook after the Investigator has reviewed the data entered, click the Sign Subject actions button on the participant’s home page. This is located at the top of the home page. A popup window will appear. Add your username and password. You will see that your signature has been applied to the participant’s entire casebook.